Ironwood Pharmaceuticals Crescita futura

Future criteri di controllo 3/6

Si prevede che Ironwood Pharmaceuticals aumenterà gli utili e i ricavi rispettivamente del 43.5% e 8.9% all'anno, mentre si prevede che l'EPS crescerà del 41.1% all'anno.

Informazioni chiave

43.5%

Tasso di crescita degli utili

41.1%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	26.8%
Tasso di crescita dei ricavi	8.9%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Good
Ultimo aggiornamento	24 Dec 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 21

Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S

Oct 24

Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Aug 16

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough

Jun 27

Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC

Jun 20

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Feb 16

Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential

Jan 31

Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Dec 19

Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

Jul 25

An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Apr 18

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Mar 28

Ironwood Pharmaceuticals: Rinse, Wash And Repeat

Oct 05

These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Sep 28

Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh

Jul 29

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:IRWD - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2027	533	135	N/A	420	3
12/31/2026	416	84	N/A	283	4
12/31/2025	348	37	120	141	6
12/31/2024	353	22	109	125	6
9/30/2024	378	-2	124	124	N/A
6/30/2024	401	9	146	147	N/A
3/31/2024	414	-1,052	148	148	N/A
12/31/2023	443	-1,002	183	183	N/A
9/30/2023	432	-952	227	227	N/A
6/30/2023	427	-917	263	263	N/A
3/31/2023	417	182	290	290	N/A
12/31/2022	411	175	274	274	N/A
9/30/2022	421	168	259	259	N/A
6/30/2022	416	173	265	265	N/A
3/31/2022	422	527	252	252	N/A
12/31/2021	414	528	262	262	N/A
9/30/2021	413	530	249	249	N/A
6/30/2021	413	509	227	227	N/A
3/31/2021	398	143	199	199	N/A
12/31/2020	390	106	167	169	N/A
9/30/2020	399	111	140	145	N/A
6/30/2020	427	97	118	126	N/A
3/31/2020	440	84	88	97	N/A
12/31/2019	428	59	4	11	N/A
9/30/2019	433	19	-12	-8	N/A
6/30/2019	367	-153	-69	-69	N/A
3/31/2019	346	-173	-81	-82	N/A
12/31/2018	347	-194	-71	-71	N/A
9/30/2018	310	-190	-90	-89	N/A
6/30/2018	331	-71	N/A	-94	N/A
3/31/2018	315	-108	N/A	-104	N/A
12/31/2017	298	-55	N/A	-101	N/A
9/30/2017	292	-143	N/A	-110	N/A
6/30/2017	271	-143	N/A	-80	N/A
3/31/2017	260	-121	N/A	-53	N/A
12/31/2016	274	-82	N/A	-26	N/A
9/30/2016	240	-82	N/A	-26	N/A
6/30/2016	213	-96	N/A	-52	N/A
3/31/2016	187	-123	N/A	-71	N/A
12/31/2015	150	-143	N/A	-107	N/A
9/30/2015	134	-166	N/A	-110	N/A
6/30/2015	112	-161	N/A	-123	N/A
3/31/2015	91	-173	N/A	-133	N/A
12/31/2014	76	-190	N/A	-156	N/A
9/30/2014	43	-204	N/A	-175	N/A
6/30/2014	31	-224	N/A	-194	N/A
3/31/2014	34	-229	N/A	-238	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che IRWD diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Si prevede che IRWD diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede IRWD diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di IRWD ( 8.9% all'anno) crescerà più lentamente rispetto al mercato US ( 9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di IRWD ( 8.9% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di IRWD è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/01/03 04:11
Prezzo dell'azione a fine giornata	2025/01/03 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Ironwood Pharmaceuticals, Inc. è coperta da 36 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Raghuram Selvaraju	Aegis Capital Corporation
Geoffrey Meacham	Barclays
Patrick Trucchio	Berenberg

Ironwood Pharmaceuticals Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for Full Year 2024

Price target increased by 11% to US$12.67

Consensus EPS estimates fall by 50%

Price target decreased by 13% to US$14.17

Ironwood Pharmaceuticals, Inc. Revises Earnings Guidance for Its Fiscal Year 2024

Price target decreased by 9.3% to US$16.33

Recent updates

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Third quarter 2024 earnings: EPS misses analyst expectations

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for Full Year 2024

Price target increased by 11% to US$12.67

Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S

Consensus EPS estimates fall by 50%

Investor sentiment deteriorates as stock falls 20%

Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 13% to US$14.17

New minor risk - Share price stability

Ironwood Pharmaceuticals, Inc. Revises Earnings Guidance for Its Fiscal Year 2024

Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) dropped from Russell 2000 Growth-Defensive Index

Insufficient new directors

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough

Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC

Independent Chairman of the Board notifies of intention to sell stock

Independent Director recently sold US$518k worth of stock

Independent Director notifies of intention to sell stock

CEO & Director recently sold US$436k worth of stock

CEO & Director notifies of intention to sell stock

Price target decreased by 9.3% to US$16.33

Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024

First quarter 2024 earnings released: US$0.03 loss per share (vs US$0.30 profit in 1Q 2023)

Ironwood Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

New minor risk - Shareholder dilution

Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)

Price target decreased by 10% to US$18.50

New minor risk - Share price stability

New minor risk - Insider selling

Full year 2023 earnings: EPS misses analyst expectations

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2024

CEO & Director notifies of intention to sell stock

Price target increased by 11% to US$19.83

Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for the Fiscal Year 2023 and Provides Earnings Guidance for the Fiscal Year 2024

Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Consensus EPS estimates fall by 42%

Ironwood Pharmaceuticals, Inc. provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Ironwood Pharmaceuticals, Inc. Provids Earnings Guidance for the Year 2023

Ironwood Pharmaceuticals, Inc. Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting

Ironwood Pharmaceuticals, Inc. Presents Positive Final Data from Stars Nutrition, A Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity

Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Price target increased by 15% to US$16.50

Senior VP recently bought US$300k worth of stock

Ironwood Pharmaceuticals, Inc. Revises Financial Guidance for the Year 2023

New major risk - Negative shareholders equity

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old

CEO & Director notifies of intention to sell stock

CEO & Director recently sold US$364k worth of stock

Price target increased by 12% to US$14.33

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Ironwood Pharmaceuticals, Inc. Presents Results from Phase III Clinical Trial in Pediatric Patients

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

CEO & Director notifies of intention to sell stock

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Senior VP & COO recently sold US$388k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations